What is new in headache 2004?;Neues bei kopfschmerzen 2004

Aktuelle Neurologie

Volumn 31, Issue 9, 2004, Pages 425-434

  Diener, H C ^a   Limmroth, V ^a   May, A ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; APC; BISOPROLOL FUMARATE; DICLOFENAC; DIPYRONE; ELETRIPTAN; FLUNARIZINE; FROVATRIPTAN; IBUPROFEN; METOPROLOL; NAPROXEN; NARATRIPTAN; NATIL N; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN SUCCINATE; TOPIRAMATE; VALPROIC ACID; ZOLMITRIPTAN;

BRADYCARDIA; BRONCHOSPASM; COMORBIDITY; DEPRESSION; DRUG HYPERSENSITIVITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOGLYCEMIA; IMPOTENCE; LIVER DISEASE; MIGRAINE; NONHUMAN; PARESTHESIA; PARKINSONISM; PROPHYLAXIS; REVIEW; SIDE EFFECT; STOMACH PAIN; TREMOR;

EID: 9344262958     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-815008     Document Type: Review

References (108)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8, Suppl 7: 1-93
2. nd Edition. Cephalalgia 2004; 24, Suppl 1: 1-160
3. Rasmussen BK. Epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds): The Headaches. New York: Raven Press, 1993: 439-443
4. Ulrich V, Gervil M, Kyvik KO et al. Evidence of a genetic factor in migraine with aura: a population-based danish twin study. Ann Neurol 1999; 45: 242-246
5. Joutel A, Bousser M, Biousese V et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genetics 1993; 5: 40-45
6. 2+ channel gene CACNLA4. Cell 1996; 87: 543-552
7. Fusco M De, Marconi R, Silvestri L et al. Haploinsufficiency of ATP1A2 encoding the Na/K pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nature Genetics 2003; 33: 192-196
8. 2+ channel defects in migraine, ataxia and epilepsy. TiPS 1998; 19: 121-127
9. Moskowitz M, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol 2004; 55: 276-280
10. Vanmolkot K, Kors E, Hottenga J et al. Novel mutations in the Na+, K+ -ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003; 54: 360-366
11. Thomsen LL, Ostergaard E, Olesen J et al. Evidence for a separate type of migraine with aura: Sporadic hemiplegic migraine. Neurology 2003; 25: 595-601
12. Terwindt G, Kors E, Haan J et al. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch Neurol 2002; 59: 1016-1018
13. Terwindt GM, Ophoff RA, Haan J et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Neurology 1998; 50: 1105-1110
14. Chapman K, Szczygielski B, Toth C et al. Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A. Headache 2003; 43: 892-895
15. Wang S, Fuh J, Lu S et al. Migraine prevalence during menopausal transition. Headache 2003; 43: 470-478
16. Winner P, Wasiewski W, Gladstein J et al. Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria. Headache 1997; 37: 545-548
17. Winner P, Rothner A, Putnam D et al. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database. Headache 2003; 43: 451-457
18. Evans R, Lipton R, Silberstein S. The prevalence of migraine in neurologists. Neurology 2003; 61: 1271-1272
19. Kruit M, Buchem M van, Hofman P et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291: 427-434
20. Harno H, Hirvonen T, Kaunisto M et al. Subclinical vestibulocerebellar dysfunction in migraine with and without aura. Neurology 2003; 61: 1748-1752
21. Chang CL, Donaghy M, Poulter N et al. Migraine and stroke in young women: case-control study. BMJ 1999; 318: 13-18
22. nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 529-542
23. Diener H, Welch K, Mohr JP. Migraine and stroke. In: Mohr J, Choi D, Grotta J, Wolf P (eds): Stroke. Pathophysiology, diagnosis and management. Philadelphia: Churchill Livingstone, 2004
24. Donaghy M, Chang CL, Poulter N et al. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 2002; 73: 747-750
25. Breslau N, Davis GC. Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults. Cephalalgia 1992; 12: 85-90
26. Breslau N, Schultz LR, Stewart WF et al. Headache and major depression. Is the association specific to migraine? Neurology 2000; 54: 308-313
27. Bahra A, Goadsby PJ. The comorbidity of migraine and depression: a review. Neurology and Psychiatry 1998; 2: 23-27
28. Breslau NLR, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology 2003; 60: 1308-1312
29. Lipton RB, Silberstein SD. Neurologic and psychiatric comorbidity with migraine. Neurology 1994; 44: S1-S47
30. Leniger T, Diener H-C. Migräne und Komorbidität. In: Diener H-C (Hrsg): Kopfschmerzen. Stuttgart: Thieme, 2003: 58-60
31. Sztajzel R, Genoud D, Roth S et al. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002; 13: 102-106
32. Carerj S, Narbone M, Zito C et al. Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 2003; 43: 725-728
33. Diener H-C, Hartung E, Chrubasik J et al. A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. Cephalalgia 2001; 21: 140-144
34. Leniger T, Driesch S von den, Isbruch K et al. Clinical characteristics of patients with comorbidity of migraine and epilepsy. Headache 2003; 43: 672-677
35. Leniger TD, Diener HC, Hufnagel A. Erhöhte zerebrale Erregbarkeit und "spreading depression" Ursachen für eine Komorbidität von Epilepsie und Migräne? Nervenarzt 2003; 74: 869-874
36. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19: 232-240
37. Thomas HM, Kudrow DB, Ashford E et al. A phase III multicentre, randomised, double-blind, parallel-group study of valdecoxib 40 mg vs placebo in patients with multiple moderate or severe acute migraine headaches with and without aura (abstract). Cephalalgia 2003; 23: 697
38. Diener H-C, Reches A, Pascual J et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Europ Neurol 2002; 47: 99-107
39. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322
40. Charlesworth B, Dowson A. Purdy A et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17: 653-667
41. th IHS Congress, 1997: 163-165
42. Sheftell F, O'Quinn S, Watson C et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000; 40: 103-110
43. Tfelt-Hansen P, Teall J, Rodriguez F et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748-755
44. Goldstein J, Ryan R, Jiang K et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 1998; 38: 737-747
45. Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000; 55, Suppl 2: S19-S24
46. Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156-163
47. Sandrini G, Färkkilä M, Burgess G et al. Eletriptan vs sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59: 1210-1217
48. Diener H, Ryan R, Sun W et al. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol 2004; 11: 125-134
49. Garcia-Ramos G, MacGregor E, Milliard B et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 869-876
50. Steiner T, Diener H, MacGregor E et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 942-952
51. Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001; 45: 206-213
52. Dowson AJ, Massiou H, Lainez JM et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial. Cephalalgia 2002; 22: 453-461
53. Visser WH, Vriend RHM de, Jaspers N et al. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 1996; 36: 471-475
54. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004; 55: 19-26
55. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55: 27-36
56. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43: 1075-1079
57. Mathew N, Schoenen J, Winner P et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43: 214-222
58. Färkkilä M, Olesen J, Dahlof C et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23: 463-471
59. Chia Y, Lim S, Wang S et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003; 43: 984-990
60. Mathew N, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003; 43: 962-974
61. Christie S, Göbel H, Mateos V et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2002; 49: 20-29
62. Baos V, Serrano A, Torrecilla M et al. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting. Int J Clin Pract 2003; 57: 761-768
63. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43: 729-733
64. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-321
65. Diener H-C for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999; 19: 581-588
66. Stillman M, Zajac D, Rybicki L Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004; 44: 65-69
67. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-187
68. Doods H, Hallermayer G, Wu D et al. Pharmacological profil of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129: 420-423
69. Olesen J, Diener H, Husstedt IW et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N EnglJ Med 2004; 350: 1104-1110
70. Eikermann AD, Diener HC. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. Cephalalgia 2003; 23: 344-347
71. Reuter U, Sanchez Del Rio M, Carpay J et al. Placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 2003; 23: 496-503
72. Diener H-C und die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg). Leitlinien für Diagnostik und Therapie in der Neurologie. 2. ed. Stuttgart: Thieme, 2003
73. Brandes J, Saper J, Diamond M et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-973
74. Martinez H, Londono O, Cantu-Martinez L et al. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003; 43: 1080-1084
75. Silvestrini M, Bartolini M, Coccia M et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 820-824
76. Tronvik E, Stovner L, Heide G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289: 65-69
77. Gallai V, Alberti A, Rossi C et al. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain 2003; 4: 92-96
78. Koseoglu E, Akboyraz A, Soyuer A et al. Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. Cephalalgia 2003; 23: 972-976
79. Matharu M, Bartsch T, Ward N et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2003; 127: 220-230
80. Zagami AS. Chronic tension-type headache - rational drug treatment options. CNS Drugs 1995; 4: 90-98
81. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo controlled double-blind cross-over study. Headache 1992; 32: 509-513
82. Murros K, Kataja M, Hedman C et al. Modified-release formulation of tizanidine in chronic tension-type headache. Headache 2000; 40: 633-637
83. Shimomura T, Awaki E, Kowa H et al. Treatment of tension-type headache with tizanidine hydrochloride: Its efficacy and relationship to the plasma MHPG concentration. Headache 1991; 31: 601-604
84. Holroyd K, Labus J, O'Donnell F et al. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache 2003; 43: 999-1004
85. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but no a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61: 285-290
86. Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. Cephalalgia 2004; 24: 29-36
87. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58: 354-361
88. Ekbom K, Monstad I, Prusinski A et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta neurol Scand 1993; 88: 63-69
89. Limmroth V, May A, Diener H-C. Der Stellenwert von Sumatriptan in der Anfallstherapie der Migräne und des Clusterkopfschmerzes. Nervenheilkunde 1996; 15: 100-108
90. Vliet JA Van, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study. Neurology 2003; 60: 630-633
91. Lainez M, Pascual J, Pascual A et al. Topiramate in the prophylactic treatment of cluster headache. Headache 2003; 43: 784-789
92. Leone M, Dodick D, Rigamonti A et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003; 23: 1001-1002
93. Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia 2002; 22: 815-817
94. nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 703-708
95. May A, Bahra A, Büchel C et al. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000; 55: 1328-1335
96. May A, Bahra A, Buchel C et al. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352: 275-278
97. Sprenger T, Bocker H, Tolle TR et al. Specific hypothalamic activation during a spontaneuos cluster headache attack. Neurology 2004; 62: 516-517
98. Franzini A, Ferroli P, Leone M et al. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery 2003; 52: 1095-1101
99. Leone M, Franzini A, D'Amico D et al. Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. Neurology 2001; 56, Suppl 3: A218
100. Leone M, Franzini A, Broggi G et al. Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up. J Neurol Sci 2003; 24, Suppl 2: 143-145
101. Dichgans J, Diener H-C, Gerber WD et al. Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr 1984; 109: 369-373
102. Katsarava Z, Fritsche G, Muessig M et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698
103. Limmroth V, Katsarava Z, Fritsche G et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014
104. Rozen T. Melatonin as treatment for idiopathic stabbing headache. Neurology 2003; 61: 865-866
105. Dodick DW, Mosek AC, Campbell JK. The hypnic ("alarm clock") headache syndrome. Cephalalgia 1998; 18: 152-156
106. Raskin NH. The hypnic headache syndrome. Headache 1988; 28: 534-536
107. Sibon I, Ghorayeb I, Henry P. Successful treatment of hypnic headache syndrome with acetazolamide. Neurology 2003; 61: 1157-1158
108. Higgins J, Cousins C, Owler B et al. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry 2003; 74: 1662-1666